Inclusion Criteria:  Patients who are fully informed and sign informed consent by themselves or their guardians; Patients receiving allogeneic hematopoietic stem cell transplantation; Patients with acute graft-versus-host disease of grade III-IV were diagnosed after transplantation; Patients with stable implantation of granulocytes and platelets.  Exclusion Criteria:  Patients who have received more than one transplant; Patients with overlap syndrome; Patients within six months after the failure of the first transplantation; Patients with uncontrollable active infection; Patients with recurrence of primary malignant hematopathy; Patients with donor lymphocyte infusion induced graft-versus-host disease after first intervention; Patients with serious respiratory diseases; Patients with severe renal insufficiency; Patients with serious and uncontrolled heart disease; Patients with severe hepatobiliary diseases unrelated to graft-versus host disease; Within one week patients who need to use more than 1mg/kg/d methylprednisolone for reasons other than graft-versus-host disease; patients who have participated in other clinical trials within 1 month; The researcher judges that there are other factors that are not suitable for participating